Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Beginning Cash Balance: 2021-2025

Historic Beginning Cash Balance for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $369.3 million.

  • Kiniksa Pharmaceuticals International's Beginning Cash Balance rose 63.63% to $369.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.6 million, marking a year-over-year increase of 12.44%. This contributed to the annual value of $108.0 million for FY2024, which is 12.03% down from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Beginning Cash Balance is $369.3 million, which was up 35.33% from $272.9 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Beginning Cash Balance ranged from a high of $369.3 million in Q3 2025 and a low of $97.4 million during Q4 2024.
  • Its 3-year average for Beginning Cash Balance is $217.9 million, with a median of $225.7 million in 2024.
  • Its Beginning Cash Balance has fluctuated over the past 5 years, first slumped by 39.68% in 2022, then skyrocketed by 70.26% in 2024.
  • Kiniksa Pharmaceuticals International's Beginning Cash Balance (Quarterly) stood at $190.2 million in 2021, then declined by 7.58% to $175.8 million in 2022, then tumbled by 32.96% to $117.8 million in 2023, then declined by 17.36% to $97.4 million in 2024, then surged by 63.63% to $369.3 million in 2025.
  • Its Beginning Cash Balance stands at $369.3 million for Q3 2025, versus $272.9 million for Q2 2025 and $294.8 million for Q1 2025.